The Neurobiology of Anxiety: Potential for Co-Morbidity of Anxiety and Substance Use Disorders

  • Neil McNaughton
Part of the Series in Anxiety and Related Disorders book series (SARD)


Anxiety Disorder Social Anxiety Panic Disorder Stimulant Drug Panic Disorder Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Andrews, G., Stewart, G., Morris-Yates, A., Holt, P., & Henderson, S. (1990). Evidence for a general neurotic syndrome. British Journal of Psychiatry, 157, 6–12.Google Scholar
  2. Barlow, D. H. (2002). Anxiety and its disorders: The nature and treatment of anxiety and panic. New York: The Guilford Press.Google Scholar
  3. Basoglu, M., Marks, I. M., Kiliç, C., Swinson, R. P., Noshirvani, H., Kuch, K., et al. (1994). Relationship of panic, anticipatory anxiety, agoraphobia and global improvement in panic disorder with agoraphobia treated with alprazolam and exposure. British Journal of Psychiatry, 164, 647–652.PubMedCrossRefGoogle Scholar
  4. Bienvenu, O. J., & Stein, M. B. (2003). Personality and anxiety disorders: A review. Journal of Personality Disorders, 17, 139–151.PubMedCrossRefGoogle Scholar
  5. Blanchard, D. C., Blanchard, R. J., Tom, P., & Rodgers, R. J. (1990). Diazepam changes risk assessment in an anxiety/defense test battery. Psychopharmacology (Berl), 101, 511–518.CrossRefGoogle Scholar
  6. Blanchard, R. J., & Blanchard, D. C. (1990). An ethoexperimental analysis of defense, fear and anxiety. In N. McNaughton & G. Andrews (Eds.), Anxiety (pp. 124–133). Dunedin: Otago University Press.Google Scholar
  7. Bonson, K. R., & Murphy, D. L. (1995). Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behavioural Brain Research, 73, 229–233.CrossRefGoogle Scholar
  8. Broadbear, J. H., Winger, G., & Woods, J. H. (2005). Self-administration of methohexital, midazolam and ethanol: Effects on the pituitary-adrenal axis in rhesus monkeys. Psychopharmacology, 178, 83–91.PubMedCrossRefGoogle Scholar
  9. Carter, C., Maddock, R., Zoglio, M., Lutrin, C., Jella, S., & Amsterdam, E. (1994). Panic disorder and chest pain: A sztudy of cardiac stress scintigraphy patients. American Journal of Cardiology, 74, 296–298.Google Scholar
  10. Cloninger, C. R. (1986). A unified biosocial theory of personality and its role in the development of anxiety states. Psychiatric Developments, 3, 167–226.Google Scholar
  11. Dantendorfer, K., Amering, M., Baischer, W., Berger, P., Steinberger, K., Windhaber, J., et al. (1995). Is there a pathophysiological and therapeutic link between panic disorder and epilepsy? Acta Psychiatrica Scandanavica, 91, 430–432.Google Scholar
  12. Egan, M. F., Wing, L., Li, R., Kirch, D. G., & Wyatt, R. J. (1994). Effects of chronic cocaine treatment on rat brain: Long- term reduction in frontal cortical serotonin. Biological Psychiatry, 36, 637–640.PubMedCrossRefGoogle Scholar
  13. Eysenck, H. J., & Eysenck, S. B. G. (1964). Eysenck Personality Inventory. London: University of London Press.Google Scholar
  14. Fleckenstein, A. E., Gibb, J. W., & Hanson, G. R. (2000). Differential effects of stimulants on monoaminergic transporters: Pharmacological consequences and implications for neurotoxicity. European Journal of Pharmacology, 406, 1–13.PubMedCrossRefGoogle Scholar
  15. Fontaine, R. (1987). Comparison of withdrawal of buspirone and diazepam: A placebo controlled study. Progress in Neuropsychopharmacology and Biological Psychiatry, 11, 189–197.CrossRefGoogle Scholar
  16. Franklin, J. A. (1990). Behavioural treatment for panic disorder. In N. McNaughton & G. Andrews (Eds.), Anxiety (pp. 84–91). Dunedin: University of Otago.Google Scholar
  17. Goisman, R. M., Warshaw, M. G., Steketee, G. S., Fierman, E. J., Rogers, M. P., Goldenberg, I., et al. (1995). DSM-IV and the disappearance of agoraphobia without a history of panic disorder: New data on a controversial diagnosis. American Journal of Psychiatry, 152, 1438–1443.PubMedGoogle Scholar
  18. Gray, J. A. (1970). The psychophysiological basis of introversion- extraversion. Behaviour Research and Therapy, 8, 249–266.PubMedCrossRefGoogle Scholar
  19. Gray, J. A. (1982). The Neuropsychology of anxiety: An enquiry in to the functions of the septo-hippocampal system. Oxford: Oxford University Press.Google Scholar
  20. Gray, J. A., & McNaughton, N. (2000). The Neuropsychology of anxiety: An enquiry into the functions of the septo-hippocampal system. (2nd ed.). Oxford: Oxford University Press.Google Scholar
  21. Griebel, G., Blanchard, D. C., Jung, A., Lee, J. C., Masuda, C. K., & Blanchard, R. J. (1995). Further evidence that the Mouse Defense Test Battery is useful for screening anxiolytic and panicolytic drugs: Effects of acute and chronic treatment with alprazolam. Neuropharmacology, 34, 1625–1633.PubMedCrossRefGoogle Scholar
  22. Gurguis, G. N. M., Antai-Otong, D., Vo, S. P., Blakeley, J. E., Orsulak, P. J., Petty, F., et al. (1999). Adrenergic receptor function in panic disorder – I. Platelet α2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. Neuropsychopharmacology, 20, 162–176.PubMedCrossRefGoogle Scholar
  23. Haefely, W., Facklam, M., Schoch, P., Martin, J. R., Bonetti, E. P., Moreau, J.-L., et al. (1992). Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders. In G. Biggio, A. Concas, & E. Costa (Eds.), GABAergic Synaptic Transmission (pp. 379–394). New York: Raven Press.Google Scholar
  24. Harkness, K. L., Monroe, S. M., Simons, A. D., & Thase, M. (1999). The generation of life events in recurrent and non-recurrent depression. Psychological Medicine, 29, 135–144.PubMedCrossRefGoogle Scholar
  25. Heikkinen, M. E., Aro, H. M., Henriksson, M. M., Isometsä, E. T., Sarna, S. J., Kuoppasalmi, K. I., et al. (1994). Differences in recent life events between alcoholic and depressive nonalcoholic suicides. Alcoholism: Clinical and Experimental Research, 18, 1143–1149.CrossRefGoogle Scholar
  26. Holt, P. (1990). Panic disorder: Some historical trends. In N. McNaughton & G. Andrews (Eds.), Anxiety (pp. 54–65). Dunedin: University of Otago Press.Google Scholar
  27. Kapczinski, F., Curran, H. V., Gray, J., & Lader, M. (1994). Flumazenil has an anxiolytic effect in simulated stress. Psychopharmacology (Berl), 114, 187–189.CrossRefGoogle Scholar
  28. Kendler, K. S., Neale, M. C., Kessler, R. C., Heath, A. C., & Eaves, L. J. (1992). Major depression and generalized anxiety disorder: Same genes, (partly) different environments? Archives of General Psychiatry, 49, 716–722.PubMedGoogle Scholar
  29. Kendler, K. S., Thornton, L. M., & Gardner, C. O. (2000). Stressful life events and previous episodes in the etiology of major depression in women: An evaluation of the “kindling” hypothesis. American Journal of Psychiatry, 157, 1243–1251.PubMedCrossRefGoogle Scholar
  30. Klein, D. F. (1995). Recognising panic disorder. European Journal of Psychiatry, 10(Suppl. 2), 61S–63S.CrossRefGoogle Scholar
  31. Kostowski, W., & Biéeacutenkowski, P. (1999). Discriminative stimulus effects of ethanol: Neuropharmacological characterization. Alcohol, 17, 63–80.PubMedCrossRefGoogle Scholar
  32. Krueger, R. F., & Tackett, J. L. (2003). Personality and psychopathology: Working toward the bigger picture. Journal of Personality Disorders, 17, 109–128.PubMedCrossRefGoogle Scholar
  33. Lader, M., & Tyrer, P. (1975). Vegetative system and emotion. In L. Levi (Ed.), Emotions: Their parameters and measurement. New York: Raven Press.Google Scholar
  34. LeDoux, J. E. (1994). Emotion, memory and the brain. Scientific American, 270, 50–59.PubMedCrossRefGoogle Scholar
  35. LeDoux, J. E. (1996). The Emotional Brain. New York: Simon and Schuster.Google Scholar
  36. MacDonald, A. B., Baker, J. M., Stewart, S. H., & Skinner, M. (2000). Effects of alcohol on the response to hyperventilation of participants high and low in anxiety sensitivity. Alcoholism: Clinical and Experimental Research, 24, 1656–1665.CrossRefGoogle Scholar
  37. Margraf, J., & Ehlers, A. (1990). Biological models of panic disorder and agorophobia: Theory and evidence. In G. D. Burrows, M. Roth, & R. Noyes (Eds.), Handbook of Anxiety (pp. 79–139). Amsterdam: Elsevier.Google Scholar
  38. Marks, I. M. (1969). Fears and phobias. London: Heinemann.Google Scholar
  39. Marks, I. M. (1988). The syndromes of anxious avoidance: Classification of phobic and obsessive-compulsive phenomena. In R. Noyes, Jr., M. Roth, & G. D. Burrows (Eds.), Handbook of Anxiety: Vol. 2. Classification, etiological factors and associated disturbances (pp. 109–146). Amsterdam: Elsevier Science Publishers.Google Scholar
  40. McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., et al. (2000). Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABAA receptor a1 subtype. Nature Neuroscience, 3, 587–592.PubMedCrossRefGoogle Scholar
  41. McNaughton, N. (1985). Chlordiazepoxide and successive discrimination: Different effects on acquisition and performance. Pharmacology, Biochemistry and Behavior, 23, 487–494.CrossRefGoogle Scholar
  42. McNaughton, N. (2002). Aminergic transmitter systems. In H. D'haenen, J. A. Den Boer, H. Westenberg, & P. Willner (Eds.), Textbook of Biological Psychiatry (pp. 895–914). Chichester: John Wiley & Sons.CrossRefGoogle Scholar
  43. McNaughton, N., & Coop, C. F. (1991). Neurochemically dissimilar anxiolytic drugs have common effects on hippocampal rhythmic slow activity. Neuropharmacology, 30, 855–863.PubMedCrossRefGoogle Scholar
  44. McNaughton, N., & Corr, P. J. (2004). A two-dimensional neuropsychology of defense: Fear/anxiety and defensive distance. Neuroscience and Biobehavioral Reviews, 28, 285–305.PubMedCrossRefGoogle Scholar
  45. McNaughton, N., Panickar, K. S., & Logan, B. (1996). The pituitary-adrenal axis and the different behavioral effects of buspirone and chlordiazepoxide. Pharmacology,Biochemistry and Behavior, 54, 51–56.CrossRefGoogle Scholar
  46. Middleton, H. C., Ashby, M., & Robbins, T. W. (1994). Reduced plasma noradrenaline and abnormal heart rate variability in resting panic disorder patients. Biological Psychiatry, 36, 847–849.PubMedCrossRefGoogle Scholar
  47. Noyes, R., Jr., Burrows, G. D., Reich, J. H., Judd, F. K., Garvey, M. J., Norman, T. R., et al. (1996). Diazepam versus alprazolam for the treatment of panic disorder. Journal of Clinical Psychiatry, 57, 349–355.PubMedGoogle Scholar
  48. Pirker, S., Schwarzer, C., Wieselthaler, A., Sieghart, W., & Sperk, G. (2005). GABAA receptors: Immunocytochemical distribution of 13 subunits in the adult rat brain. Neuroscience, 101, 815–850.CrossRefGoogle Scholar
  49. Randall, P. K., Bremner, J. D., Krystal, J. H., Nagy, L. M., Heninger, G. R., Nicolaou, A. L., et al. (1995). Effects of the benzodiazepine antagonist flumazenil in PTSD. Biological Psychiatry, 38, 319–324.PubMedCrossRefGoogle Scholar
  50. Richardson, D. K., Reynolds, S. M., Cooper, S. J., & Berridge, K. C. (2005). Endogenous opioids are necessary for benzodiazpine palatability enhancement: Naltrexone blocks diazepam-induced increase of sucrose-'liking'. Pharmacology, Biochemistry and Behavior, 81, 657–663.CrossRefGoogle Scholar
  51. Rickels, K., & Rynn, M. (2002). Pharmacotherapy of generalized anxiety disorder. Journal of Clinical Psychiatry, 63, 9–16.PubMedGoogle Scholar
  52. Roy-Byrne, P. (2005). The GABA-benzodiazepine receptor complex: Structure, function and role in anxiety. Journal of Clinical Psychiatry, 66, 14–20.PubMedCrossRefGoogle Scholar
  53. Shear, M. K., & Maser, J. D. (1994). Standardized assessment for panic disorder research: A conference report. Archives of General Psychiatry, 51, 346–354.PubMedGoogle Scholar
  54. Shipley, M. T., Ennis, M., Rizvi, T. A., & Behbehani, M. M. (1991). Topographical specificity of forebrain inputs to the midbrain periaqueductal gray: Evidence for discrete longitudinally organized input columns. In A. Depaulis & R. Bandler (Eds.), The Midbrain Periaqueductal Gray Matter (pp. 417–448). New York: Plenum Press.Google Scholar
  55. Spielberger, C. D., Gorusch, R. L., Lushene, R., Vagg, P. R., & Jacobs, G. A. (1983). Manual for the State-Trait Anxiety Inventory (Form Y). Palo Alto: Consulting Psychologists Press.Google Scholar
  56. Stein, D. J., Hollander, E., Mullen, L. S., DeCaria, C. M., & Liebowitz, M. R. (1992). Comparison of clomipramine, alprazolam and placebo in the treatment of obsessive-compulsive disorder. Human Psychopharmacology, 7, 389–395.CrossRefGoogle Scholar
  57. Stein, D. J., Vythilingum, B., & Seedat, S. (2004). Pharmacotherapy of phobias. In M. Maj (Ed.), Evidence and Experience in Psychiatry: Vol. 7. Phobias. Chichester: John Wiley & Sons, Ltd.Google Scholar
  58. Stevens, J. C., & Pollack, M. H. (2005). Benzodiazepines in clinical practice: Consideration of their long-term use and alternative agents. Journal of Clinical Psychiatry, 66, 21–27.PubMedGoogle Scholar
  59. Tanaka, M., Yoshida, M., Emoto, H., & Ishii, H. (2000). Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: Basic studies. European Journal of Pharmacology, 405, 397–406.PubMedCrossRefGoogle Scholar
  60. Teicher, M. H. (1988). Biology of anxiety. Medical Clinics of North America, 72, 791–814.PubMedGoogle Scholar
  61. Trimble, M. R. (1990). Benzodiazepines in clinical practice. In D. Wheatley (Ed.), The Anxiolytic Jungle: Where next? (pp. 9–21). Chichester: John Wiley & Sons.Google Scholar
  62. Tripp, G., & McNaughton, N. (1987). Naloxone fails to block the effects of chlordiazepoxide on acquisition and performance of successive discrimination. Psychopharmacology, 91, 119–123.PubMedCrossRefGoogle Scholar
  63. Tripp, G., McNaughton, N., & Oei, T. P. S. (1987). Naloxone blocks the effects of chlordiazepoxide on acquisition but not performance of differential reinforcement of low rates of response (DRL). Psychopharmacology, 91, 112–118.PubMedCrossRefGoogle Scholar
  64. Tyrer, P., Seivewright, H., & Johnson, T. (2003). The core elements of neurosis: Mixed anxiety-depression (cothymia) and pesonality disorder. Journal of Personality Disorders, 17, 129–138.PubMedCrossRefGoogle Scholar
  65. Van Ree, J. M., Niesink, R. J. M., van Wolfswinkel, L. V., Ramsey, N. F., Kornet, M. W., van Furth, W. R., et al. (2000). Endogenous opioids and reward. European Journal of Pharmacology, 405, 89–101.PubMedCrossRefGoogle Scholar
  66. Westenberg, H. G. M. (1999). Facing the challenge of social anxiety disorder. European Neuropsychopharmacology, 9, S93–S99.PubMedCrossRefGoogle Scholar
  67. Wheatley, D. (1990). The new alternatives. In D. Wheatley (Ed.), The Anxiolytic Jungle: Where Next? (pp. 163–184). Chichester: John Wiley.Google Scholar
  68. Zhu, X. O., & McNaughton, N. (1995). Similar effects of buspirone and chlordiazepoxide on a fixed interval schedule with long-term, low-dose administration. Journal of Psychopharmacology, 9, 326–330.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Neil McNaughton
    • 1
  1. 1.Dept. PsychologyUniversity of OtagoDunedinNew Zealand

Personalised recommendations